Skin Disorders News

Dupixent for atopic dermatitis has received a label update from the FDA adding phase 3 efficacy and safety data, Regeneron and Sanofi announced in a press release.

According to analyses of new phase 3 data, patients with atopic dermatitis that were treated with Vtama cream 1% maintained long-term improvement even after stopping treatment, Dermavant announced in a press release.

Careers in allergy and asthma can take physicians into private, corporate or academic work as well as into professional organizations. Michael S. Blaiss, MD, a new member of Healio’s Allergy/Asthma Peer Perspective Board, has done it all.

ANAHEIM, Calif. — A woman who used an acrylate screen protector on her cell phone developed a rash on her face and fingers, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Patients with hereditary angioedema who used berotralstat generally tolerated treatment and experienced reductions in attacks over 96 weeks, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Healio’s top atopic dermatitis stories described evidence supporting various treatments, including two reviews of dozens of approaches, as well as physical and mental comorbidities, among other topics.

The FDA has accepted a biologics license application for garadacimab as a monthly prophylactic treatment for hereditary angioedema, according to a press release from the manufacturer.

Two new practice parameters from a joint task force published in Annals of Allergy, Asthma & Immunology provide evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis.

ANAHEIM, Calif. — A patient with hereditary angioedema and a plasminogen gene mutation did not have any attacks with tranexamic acid, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ANAHEIM, Calif. — The addition of leukotriene receptor antagonists to antihistamines improved urticaria severity with little to no impact on adverse events, according to a systematic review and meta-analysis.